Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety
April 12, 2021 08:00 ET
|
Amunix Pharmaceuticals, Inc.
AMX-818 is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated T cell engager) platform designed to improve the toxicity profile of T cell engagers for the treatment of HER2-expressing...
Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020
December 09, 2020 09:00 ET
|
Amunix Pharmaceuticals, Inc.
– Data demonstrate potential of Amunix’s XPAT (XTENylated Protease-Activated T cell engager) platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating...
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
September 17, 2020 07:00 ET
|
Amunix Pharmaceuticals, Inc.
– Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors – – Masked prodrug...
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
June 22, 2020 09:00 ET
|
Amunix Pharmaceuticals, Inc.
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid...
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality
May 27, 2020 07:00 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
Amunix Raises $73 Million in Series A Financing Led by Omega Funds
March 04, 2020 07:00 ET
|
Amunix Pharmaceuticals, Inc.
-- Harnessing clinically validated prodrug technology to advance novel pipeline of T cell engager and cytokine agents that are selectively activated in the tumor microenvironment -- -- Proprietary T...
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer
August 27, 2019 07:03 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
June 26, 2019 07:05 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...